Freenome Holdings
Latest round
- Series F
Last raised
- Feb 2024
Total raised
- $1.3B
Investors
- 47
About Freenome Holdings
Freenome Holdings, Inc.S.Freenome Holdings, Inc. specializes in developing innovative cancer screening platforms that leverage artificial intelligence and multiomics technology. Charles Roberts, the founder, has a history of previous entrepreneurial ventures.Freenome specializes in early cancer detection through its innovative screening platform that integrates advanced science with artificial intelligence. The core product offerings revolve around multiomics technology, which utilizes a standard blood draw to identify cancer in its earliest and most treatable stages. This intelligent screening platform aims to address critical healthcare challenges by enabling timely interventions for cancer patients, thereby improving treatment outcomes. Freenome's services are designed for healthcare providers, oncologists, and clinical laboratories, ensuring that end users—patients and their families—receive accurate and accessible cancer screening solutions.Freenome generates revenue through partnerships with healthcare institutions and clinical labs that integrate its screening solutions into their services. The transactions are structured primarily as B2B agreements, allowing healthcare providers to offer Freenome’s cancer detection tests to their patients. The company promotes its flagship offerings, including the FREENOME® test and the PREEMPT CRC® study, through subscription models and service agreements tailored to the needs of its clients. These partnerships enhance the clinical workflow while providing Freenome a steady revenue stream as healthcare providers incorporate its products into their routine cancer screening protocols. Freenome plans to launch new products designed for enhanced cancer detection and is targeting expansion into international markets as it achieves clinical validations and regulatory approvals.
Who invested in Freenome Holdings
47 investors across 8 rounds
See all investors in Freenome Holdings
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series F
Feb 15, 2024
Amount
$254M
Investors
Series E
Jan 11, 2022
Amount
$290M
Investors
Series D
Nov 22, 2021
Amount
$243M
Investors
Series C
Aug 14, 2020
Amount
$270M
Investors
Series B
Jun 24, 2019
Amount
$160M
Investors
Series A
Aug 14, 2017
Amount
$8.1M
Investors
Series A
Feb 23, 2017
Amount
$64M
Investors
Seed
May 23, 2016
Amount
$5.5M
Investors
Questions about Freenome Holdings
Who invested in Freenome Holdings?
Freenome Holdings has 47 investors on record across 8 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Freenome Holdings raised?
Freenome Holdings has raised 8 venture rounds. Sign up free to see how much each round raised and the total.
When did Freenome Holdings last raise money?
Freenome Holdings's most recent round on record is a Series F, in Feb 2024.
What does Freenome Holdings do?
Freenome Holdings is a biotechnology company.
Where is Freenome Holdings headquartered?
Freenome Holdings is headquartered in Brisbane, US.
Which VCs invest in companies like Freenome Holdings?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Freenome Holdings's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series F
Raising like Freenome Holdings? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.